As CDK13 mel acts via a dominant negative mechanism and no CDK13 mel mutations are 126 observed in the Cyclin binding domain, we hypothesized that Cyclin binding is required for 127 CDK13 mel dominant negative activity. To test whether the canonical CDK13 Cyclin, 128 CCNK 18,22,23 , or the related CCNT1 are required for CDK13 mel dominant negative 129 melanomagenesis in vivo, we co-injected vectors that express melanocyte-specific CDK13 mel and 130 melanocyte-specific CRISPR of ccnK or ccnT1 in the mitfa -/-; BRAF; p53 -/zebrafish melanoma 131 model. ccnK melanocyte-specific CRISPR expedited melanoma in the presence of CDK13 W878L , 132 but not alone ( Figure S1L-M) . ccnT1 melanocyte-specific CRISPR suppressed CDK13 W878L and 133 CDK13 R860Q oncogenesis but had no effect by itself ( Figure 1K-L, S1O) . PCR across the 134 CRISPR cut site confirmed indels directed by the ccnT1, ccnK, and control gRNAs (Figure  135   S1N ). These data indicate that CDK13 mel oncogenesis requires CCNT1 for its dominant negative 136 oncogenic activity. 137
Transcriptional Cyclin Dependent Kinases modulate RNA Polymerase II function to impact gene 24 expression. Here, we show that CDK13 is mutated in 4% of patient melanomas and mutation or 25 downregulation is associated with poor overall survival. Mutant CDK13 lacks kinase activity and 26 overexpression in zebrafish leads to accelerated melanoma. CDK13 mutant fish and human 27 melanomas accumulate prematurely terminated RNAs that are translated into truncated proteins. 28 CDK13 binds to and regulates the phosphorylation of ZC3H14, a member of the PolyA 29 eXosome Targeting (PAXT) RNA degradation complex. ZC3H14 phosphorylation recruits the 30 PAXT complex to degrade prematurely terminated polyadenylated transcripts in the nucleus. In 31 the presence of mutant CDK13, ZC3H14 phosphorylation is compromised and consequently fails 32 to recruit the PAXT complex, leading to truncated transcript stabilization. This work establishes 33 a role for CDK13 and the PAXT nuclear RNA degradation complex in cancer and has prognostic 34 significance for melanoma patients with mutated or downregulated CDK13. 35 36 Transcriptional Cyclin Dependent Kinases (CDKs) are a phylogenetically-related family of 37 kinases that are activated by a cyclin binding partner 1 and have roles in transcriptional 38 subprocesses including initiation, elongation, and recruitment of complexes engaged in 39 cotranscriptional RNA processing 2-5 . Transcriptional CDKs are being explored as drug targets 40 for many difficult-to-treat cancers [6] [7] [8] [9] . Additionally, mutations affecting one of the transcriptional 41 CDKs, CDK13, have recently been found to cause syndromic developmental disorders that affect 42 neural-crest derived tissues 10,11 including heart and craniofacial developmental anomalies. 43
However, the role of CDK13 in transcription and RNA processing remains poorly understood 44 and no functional role for CDK13 has been defined in cancer. 45 RNA polymerase II (RNAPII), the enzyme that transcribes pre-messenger RNA from 46 protein-coding genes, is exquisitely regulated at multiple steps to ensure transcriptional initiation, elongation, and termination are precisely executed. During active elongation, a rapid 48 cascade of a vast number of RNA processing steps takes place 12 . Given this complexity, RNA 49 processing errors can occur, resulting in defective transcripts that must be degraded by the 50 nuclear exosome in order to prevent their translation into truncated proteins 15, 16 . 51
The nuclear exosome degrades aberrant or unstable nuclear RNAs. Three different human 52 adaptor complexes have been discovered to date, each of which associates with and directs a 53 specific class of nuclear RNAs for exosomal degradation. All three adaptor complexes include 54 the MTR4 helicase, paired with proteins that recognize distinct RNA species. The TRAMP 55 complex targets aberrant nucleolar ribosomal RNAs while the NEXT complex targets PROMoter 56 uPstream Transcripts (PROMPTs) and enhancer RNAs for destruction 13 . The recently reported 57
PolyA tail eXosome Targeting (PAXT) complex degrades prematurely terminated 58 polyadenylated RNAs and requires the adaptor protein ZFC3H1 14, 15 . It is unknown how PAXT-59 mediated RNA degradation is regulated. 60
In this study, we show that mutations in CDK13 occur in melanoma and promote tumor 61 formation and growth. The accelerated tumor progression in melanomas is dependent on Cyclin 62 T1 (CCNT1) rather than the canonical CDK13 cyclin partner, Cyclin K (CCNK). When CDK13 63 is mutated, ZC3H14 phosphorylation is compromised, and consequently the nuclear RNA 64 exosome fails to be recruited to prematurely terminated polyadenylated RNAs. Failure to recruit 65 the nuclear RNA exosome to prematurely truncated transcripts results in accumulation of 66 aberrant RNAs and the production of truncated proteins in melanoma. This work uncovers a role 67 for the PAXT nuclear RNA exosome in human cancer and defines its regulation by CDK13. 68
Results 70 CDK13 is a melanoma tumor suppressor. 71 We examined the transcriptional CDK loci in melanoma patient samples and found CDK13 is 72 mutated in 4% (22/520 cases) of cutaneous melanomas, with 9 distinct missense mutations 73 occurring in the kinase domain, and 7 of these mutations near the ATP-binding site ( Figure 1A) . 74 Surprisingly, many of the same amino acid changes were found in CDK13-associated 75 developmental syndromes 10 , suggesting a specific activity of these mutations. Survival analysis 76 of human TCGA data revealed that CDK13 downregulation (z score  -1.0) or mutation 77 (CDK13-altered) correlated with decreased overall survival [median CDK13-altered survival of 78 48.8 months vs. remaining case survival of 102 months 16,17 ( Figure 1B) ]. Patients initially staged 79 with 0/1/2 melanoma that had CDK13-alterations exhibited reduced overall survival compared to 80 remaining stage 1/2 melanoma patients ( Figure S1A ). CDK13 melanoma mutations near the 81 ATP-binding site were plotted onto the crystal structure ( Figure 1C ) 18 and 6/7 of these mutations 82 were predicted to eliminate kinase activity by disruption of T-loop activation (R860Q or P869S), 83 alteration of the substrate binding pocket (W878L), or disruption of the kinase domain structure 84 (P881L, P893L, and I843N). In vitro, CDK13 WT activated by the typical cyclin partner, CCNK, 85 had robust kinase activity while the R860Q, W878L, and K734R mutants failed to phosphorylate 86 full-length RNAPII C-terminal domain (CTD) and a second substrate ( Figure 1D , S1B). As a 87 control, we included the catalytically-dead CDK13 K734R mutation, which replaces the lysine 88 required for catalysis of all known kinases. In summary, these data suggest that CDK13 is 89 mutated in melanoma, mutations abrogate CDK13 kinase activity, and mutation or 90 downregulation of CDK13 in patient melanomas is associated with decreased overall survival. 91
To examine cdk13 loss in melanoma, we used a BRAF V600E ; p53-/-; mitfa-/-zebrafish 92 melanoma model 19 in which Cas9 was expressed in melanocytes using the mitfa promoter and 93 either a cdk13 gRNA or a control gRNA was ubiquitously expressed. Zebrafish lacking cdk13 94 showed significantly decreased numbers of melanocytes as compared with zebrafish expressing a 95 control gRNA, indicating that cdk13 is required for normal melanocyte development ( Figure 1E , 96 1F, S1D vs. S1C). Overexpression of human wild-type CDK13 (CDK13 WT ) resulted in fewer 97 melanocytes during development ( Figure 1E , 1F, S1E). Injection of a cdk13 gRNA/Cas9-98 expressing vector and human CDK13 WT rescued melanocyte numbers in the melanoma model 99 ( Figure 1E , 1F, S1F). These data show that tightly-controlled levels of cdk13 are required for 100 melanocyte development and that human CDK13 can complement the loss of the zebrafish gene. 101
Rarely, melanomas arose in zebrafish with cdk13 melanocyte-specific CRISPR deletion, and 102 these tumors appeared to grow faster than melanomas with intact cdk13. Phospho-histone 3 103 (PH3) immunohistochemical (IHC) staining of melanomas with cdk13 gRNA and a control 104 gRNA revealed that cdk13 CRISPR-deleted tumors were significantly more proliferative than 105 melanomas with retained cdk13 (Figure 1G , S1H). PCR across the CRISPR cut site confirmed 106 frameshift indels, and more in-frame indels were observed in cdk13 gRNA compared to control 107 gRNA melanomas ( Figure S1G ). These data suggest that melanocytes with loss of cdk13 may be 108 selected against during development, but surviving melanocytes give rise to highly proliferative 109
melanomas. 110
To test whether CDK13 melanoma-associated mutations cause more aggressive melanoma 111 in vivo, mutant CDK13 was expressed in melanocytes in a BRAFV600E; p53-/-; mitfa-/-112 zebrafish melanoma model 20,21 . Control melanocyte-specific EGFP expression resulted in 113 expected mosaic zebrafish stripes, whereas human CDK13 WT expression resulted in dramatically 114 fewer melanocytes at 9wpf ( Figure 1H , S1I). In contrast, melanocyte-specific overexpression of 115 CDK13 R860Q , CDK13 P869S , CDK13 W878L , CDK13 P881L , and CDK13 P893L caused the appearance of 116 black patches at 9wpf ( Figure 1H , S1I) and expedited tumor onset ( Figure 1I , S1J). 117
Overexpression of the catalytically-dead CDK13 K734R mutant also caused black patches at 9wpf 118 and expedited tumor onset ( Figure 1H , 1I, S1I). CDK13 W878L-and P893L-expressing 119 melanomas had more PH3-positive cells than control EGFP melanomas by IHC ( Figure 1J , 120 S1K). Because all CDK13 mutations promoted melanoma to a similar degree, we have used them 121 interchangeably in most assays, and refer to them collectively hereafter as CDK13 mel . Since both 122 CRISPR-mediated deletion and CDK13 mel expression in zebrafish caused more proliferative 123 melanomas, our data suggest that CDK13 mel mutations act through a dominant negative 124 mechanism. 125 CTD ( Figure 1D ), chromatin immunoprecipitation sequencing (ChIP-seq) was used to determine 140 the localization of CDK13 mel on melanoma chromatin. ChIP-seq was performed on 141 approximately equal cell numbers gathered from EGFP and CDK13 W878L -expressing zebrafish 142 melanomas (Figure 2A ). EGFP-expressing melanomas were used as the ChIP-seq control since 143 zebrafish expressing CDK13 WT had very few melanocytes and rarely developed melanoma. 144
ChIP-seq from EGFP melanomas showed zebrafish Cdk13 was especially enriched at 145 transcriptional start sites (TSSs) ( Figure 2B , left, green). CDK13 W878L overexpression in 146 melanoma resulted in increased CDK13 signal at TSSs ( Figure 2B , left, black). CDK13 W878L 147 bound to genes with Cdk13 WT occupancy in control melanomas and the amount of CDK13 W878L 148 bound correlated with the amount of Cdk13 WT bound in control melanomas ( Figure 2C ). 149
To determine whether mutant CDK13 also bound chromatin in human melanoma cells, 150 CLOVER fluorescent protein, CDK13 WT , CDK13 W878L , or CDK13 R860Q were expressed in 151 human A375 melanoma cells ( Figure 2E ). Cells expressing either CDK13 mel protein grew more 152 quickly than cells expressing CDK13 WT or CLOVER ( Figure 2F , Figure S2A ). CDK13 R860Q also 153 bound chromatin loci previously bound by CDK13 WT , similar to the findings in zebrafish 154 melanomas ( Figure 2G -H). Because CDK13 mel binds chromatin at sites normally bound by 155 CDK13 WT , CDK13 mel is positioned to interfere with CDK13 WT kinase activity and thus act in a 156 dominant negative manner in zebrafish and human melanoma cells. 157
As CDK13 mel bound chromatin, we next sought to determine if CDK13 mel disrupted RNAPII 158 occupancy. ChIP-seq was performed with antibodies that recognize either RNAPII (anti-159 8WG16), or RNAPII phosphorylated at the CTD Serine-2 position (anti-Ser2p), a modification 160 of elongating RNAPII involved in the recruitment of RNA processing machinery 12,25,26 . 161
Zebrafish melanomas expressing CDK13 W878L exhibited perturbed RNAPII as compared to control melanomas, with a notable decrease in TSS-proximal RNAPII and a slight increase gene 163 body RNAPII ( Figure 2D ). Ser2p RNAPII occupancy was also perturbed; genes with the highest 164 increase in CDK13 mel binding had increased Ser2p ( Figure S2B , left). When the Ser2p RNAPII 165 signal was normalized to total RNAPII, a dramatic increase in Ser2P RNAPII was observed at 166 the promotor-proximal region ( Figure S2C RNAPII was more perturbed on highly expressed genes ( Figure S2D -E), however there was no 173 correlation with gene length (S2F-G). These data show CDK13 mel expression perturbed RNAPII 174 occupancy on highly expressed genes, suggesting that CDK13 normally acts via a mechanism 175 important on highly expressed genes. 176
Notably, changes in the distribution of the Ser2p signal upon CDK13 mel expression differed 177 distinctly from those observed upon loss of a close paralog, CDK12. In cells lacking CDK12, 178
Ser2p was strongly decreased across the gene body despite an increase in total RNAPII 28 . These 179 data also suggest that CDK13 mel promotes oncogenesis via a mechanism that is distinct from 180
CDK12. 181

Mutant CDK13 causes accumulation of prematurely-terminated RNAs. 182
To determine the transcriptional impact of CDK13 mel in zebrafish melanomas, RNA 183 sequencing (RNA-seq) was conducted on BRAF; p53-/-; mitfa-/-zebrafish melanomas 184 expressing EGFP (n=4) or mutant CDK13 (R860Q, n=5; K734R, n=5, Figure S3A ). Differential 185 expression reassuringly showed the most differentially expressed gene in the zebrafish 186 melanomas was human CDK13 mel . 158 downregulated and 53 upregulated genes with a q value 187 <0.05 were identified. Panther GO-Slim Biologic Process pathway analysis of upregulated genes 188 showed no pathway enrichment, while downregulated genes were enriched for 1) positive 189 regulation of GTPase activity (q=1.63x10-7), 2) cellular response to tumor necrosis factor (TNF) 190 (q=1.64x10-7), and 3) granulocyte chemotaxis (q=1.61x10-7). 191
As CDK13 is phylogenetically related to known transcriptional kinases CDK9 and CDK12, 192 and CDK13 mel expression caused a perturbation in RNAPII occupancy, we tested for a global 193 RNA defect by quantifying differential exon expression. RNA differential expression analysis of 194 first (F), alternative first (AF), internal (I), last (L), or alternative last (AL) exons in each gene 195 were quantified genome-wide in zebrafish melanomas. Many genes exhibited increased read 196 coverage in the first exon as compared to the last exon in CDK13 mel expressing as compared with 197 control melanomas (p=2.2x10 -16 , two-sided Wilcoxon rank sum test) ( Figure 3A ). These data 198
show that prematurely terminated transcripts containing the 5' but not the 3' end of the gene are 199 present in CDK13 mel zebrafish melanomas. 200
To test whether CDK13 mel mutations have a similar effect on RNAs in patient melanomas, 201 we analyzed polyA-selected RNAseq data from TCGA data. Melanomas with kinase domain 202 mutations (n=3) were compared to matched wild-type controls (n=5). Similar to zebrafish 203 melanomas, increased read coverage in the first exon versus the last exon was observed in 204 CDK13 mel as compared to CDK13 WT patients (p=2.2x10 -16 , two-sided Wilcoxon rank sum test) 205 ( Figure 3B ). One example gene that was significantly affected in patient samples was TRIM25 206
( Figure 3D ). The evidence for prematurely terminated RNAs was of greater magnitude in polyA-207 selected RNA-seq, consistent with the prematurely terminated transcripts being polyadenylated. 208
These data demonstrate that CDK13 mel expression in both zebrafish and human melanomas 209 results in the accumulation of prematurely terminated polyadenylated transcripts. 210
To determine whether genetic deletion of CDK13 also results in accumulation of 211 prematurely terminated transcripts, we generated mouse embryonic stem cells (mESCs) that 212
were Cdk13-/-and carried a doxycycline-inducible Cdk13 rescue transgene. After removal of 213 doxycycline for 0,48, or 72 hours, polyA-selected RNA was subjected to stranded sequencing 214 ( Figure S3B -E). Similar to zebrafish and patient melanomas expressing CDK13 mel , increased 215 first exon coverage and decreased last exon coverage was observed at 48 hours as compared to 0 216 hours in Cdk13-depleted mESCs. Cdk13-depleted mESCs exhibited an additional increase in the 217 ratio of first to last exon coverage after 72 hours ( Figure 3C ). This data further supports the 218 hypothesis that Cdk13 is required to prevent accumulation of prematurely terminated 219 polyadenylated transcripts. 220
Notably, in contrast to the increase in distinctly positioned intronic polyadenylation events 221 observed upon Cdk12 depletion 28 , we were unable to detect cleavage and polyadenylation at 222 specific sites within gene bodies. We developed an algorithm to quantify sequencing reads with 223 non-genomically encoded polyA tails that map to the distal polyA sites of genes. Using this 224 algorithm, we observed a significant decrease in the ratio of transcripts from highly expressed 225 polyadenylated genes at the distal polyA site (corresponding to the full-length mRNA) to total 226 transcript number in Cdk13-depleted mESCs ( Figure 3E ). Cdk13 depletion causes RNAs 227 terminating upstream of the normal polyA site to be either generated more frequently or 228 degraded more slowly. As a consequence, the pool of cellular transcripts contains 229 proportionately fewer full-length mRNAs. 230
Mutant CDK13 causes accumulation of truncated proteins. 231
Prematurely terminated transcripts are typically degraded by the nuclear exosome, which 232 prevents them from being exported and translated. To determine whether the prematurely 233 terminated transcripts we observed in CDK13 mel zebrafish melanomas are translated, we used 234 tandem mass spectrometry to analyze global protein expression in melanomas isolated from age-235 matched BRAF V600E ; p53-/-; mitfa-/-zebrafish with melanocyte-specific expression of CDK13 mel 236 (n=3) or EGFP (n=3). To identify consistent changes across replicates, peptides measurements 237 with a t-test result of p<0.1 were mapped. The log2-fold change in peptide measurements 238 between CDK13 mel /EGFP were binned and plotted along protein length to create a metaplot 239 ( Figure 4A , r= -0.5349 , p value=0.0001). The negative slope in the metaplot is consistent with 240 an increase in short proteins arising from the translation of prematurely terminated 241 polyadenylated transcripts. These data suggest that rather than being degraded by the nuclear 242 exosome, prematurely terminated transcripts accumulate and are translated into truncated 243 proteins in CDK13 mel expressing cells. 244
To identify specific proteins that are most impacted by CDK13 mel , two methods were used. 245
First, we assessed proteins as shown in Figure 4A that had >1 measurement and metaplot slope 246 <-1, which identified 263 truncated proteins. Second, using all data, proteins with >3 peptide 247 measurements were tested for a negative slope (log 2 CDK13 mel /EGFP, F-test p<0.05). This more 248 restrictive analysis identified 103 candidates ( Figure S4 ), 56 of which were distinct from the first 249 group. Of these 103 candidate proteins, the most significantly enriched KEGG Pathways were 250 metabolic ribosome (FDR 2.01e-07) and carbon metabolism (3.01 e-05). Several of the truncated 251 proteins we identified are predicted to lose carboxy-terminal enzymatic domains, including Ilk, 252
Crk, Ikbkb, and Cdk15 ( Figure 4B -E). Ilk, Crk, and Ikbkb have published evidence of dominant 253 negative activity upon carboxy-terminal loss 29-31 . Individual impacted proteins showed an 254 increase in truncated species at the expense of full-length proteins in CDK13 mel zebrafish 255 melanomas. These data indicate that CDK13 mel expressing zebrafish melanomas translate 256 prematurely terminated transcripts to produce truncated proteins, which we hypothesize cause 257 CDK13 mel oncogenesis via tumor suppressor loss and/or expression of dominant negative protein 258
truncations. 259
To determine whether truncated protein production correlated with CDK13 mel binding at the 260 gene locus, we overlaid the 319 truncated proteins with the top quintile of genes with enriched 261 CDK13 mel binding as determined by ChIP-seq. 133/319 truncated proteins (42%) were within the 262 top quintile of CDK13 mel enrichment. As the ChIP-seq and tandem mass spectrometry 263 experiments were done on different cohorts of primary zebrafish melanomas, and given the 264 detection limits of mass spectrometry, the overlap in this restrictive analysis suggests that genes 265 with high levels of CDK13 mel chromatin binding are more likely to accumulate prematurely 266 terminated RNAs which are translated into truncated proteins than would be expected by chance 267 (p<0.0001, Fisher's exact test). 268
Mutant CDK13 disrupts the polyA RNA exosome. 269
To elucidate how CDK13 mel expression results in the accumulation of truncated RNAs in 270 human melanoma cells, V5-tagged CDK13 WT (n=3), CDK13 W878L (n=2), or control fluorescent 271 protein CLOVER (n=3) were immunoprecipitated from nuclear extracts and co-272 immunoprecipitating proteins were identified by mass spectrometry (IP-MS) ( Figure 5A ). In the 273 CDK13 WT IP, of the 11 co-precipitating proteins identified ( Figure 5C ), 9 are RNA binding 274 proteins (q=3.04x10 -5 ) and 3 are involved in negative regulation of polyadenylated RNA 275 (q=2.73x10 -4 ) 32,33 . We found both CDK13 WT and CDK13 W878L bound to CCNT1, again 276 implicating CCNT1 as the required cyclin-binding partners for CDK13 in human melanoma cells 277 as our functional data suggested ( Figure 2J -L); surprisingly, the canonical cyclin binding partner 278 of CDK13, CCNK, was not detected above background 18, 22, 34 . This unbiased approach indicated 279 that the most significant interacting partners of CDK13 are CCNT1 and multiple factors involved 280 in RNA processing. 281
In the CDK13 WT IP, the most abundantly identified interacting protein was ZC3H14, a zinc 282 finger protein implicated in negative regulation of polyA tail length 35, 36 . ZC3H14 was also 283 recently identified as part of the PolyA tail eXosome Targeting (PAXT) complex 14 which is 284 responsible for targeting prematurely terminated polyadenylated transcripts to the nuclear 285 exosome for degradation 15 . Of the mutations observed in melanoma patients, CDK13 W878L was 286 chosen because it changes an amino acid in the substrate binding groove, which we hypothesized 287 would disrupt substrate binding ( Figure 5B ). In the CDK13 W878L IP, the ZC3H14 interaction was 288 strongly disrupted (q=0.0195) while all other protein interactors were unaffected ( Figure 5C ). 289
These data suggest that ZC3H14 binds CDK13 in the substrate binding groove and could be a 290 CDK13 substrate. 291
To identify ZC3H14 binding partners in CDK13 mel cells, the nuclear isoform of ZC3H14 292 and a control protein were tagged and transiently expressed in CDK13 mel and CDK13 WT human 293 melanoma cells ( Figure 5D ). By IP-MS, we found that the three most abundant binding partners 294 for ZC3H14 in CDK13 WT cells were THOC2, ZFC3H1, and MTR4 ( Figure 5E , black bars). 295 THOC2 functions in RNA export, ZFC3H1 functions as a linker between the PAXT and the 296 nuclear RNA degradation complex, and MTR4 is a helicase required for the function of all three 297 known nuclear RNA degradation complexes 14 . Other members of the PAXT complex were 298 identified including PABPN1 and ZC3H18. In cells expressing CDK13 mel , ZC3H14 lost 299 phosphorylation at S475 (as determined by mass spectrometry) ( Figure S5A ) and exhibited 300 decreased binding to THOC2 (q<0.0001), ZFC3H1 (q<0.0001), and MTR4 (q=0.018) but stable 301 binding to PABPN1 and ZC3H18 ( Figure 5E , blue bars). Together, these data show that CDK13 302 normally activates the recruitment of the PAXT complex to prematurely terminated 303 polyadenylated transcripts via phosphorylation of the ZC3H14 adaptor. Upon loss of CDK13 304 function, the PAXT complex is not efficiently recruited to truncated mRNAs, resulting in their 305 stabilization and translation into truncated polypeptides that promote melanomagenesis ( Figure  306 S5B). 307
Discussion 308
Our data show that CDK13 functions as a tumor suppressor in melanoma and that CDK13 mel 309 alleles promote melanomagenesis through a dominant negative mechanism requiring CCNT1. 310
We provide evidence that CDK13 mutation or loss leads to a failure to degrade prematurely 311 terminated transcripts. We found that CDK13 binds to, and may phosphorylate ZC3H14, a 312 component of the PAXT complex which is responsible for degrading polyadenylated 313 prematurely terminated RNAs. Consistent with the functional link to CDK13 that we have 314 established, ZC3H14 germline mutations also cause a neurodevelopmental disorder 37 . We 315 confirmed that ZC3H14 associates with the PAXT nuclear RNA exosome complex as recently 316 reported 14 . Upon CDK13 mel expression, we showed that ZC3H14 lost phosphorylation at S475, 317 which coincided with reduced recruitment of ZFC3H1 and MTR4. Because PAXT has been 318 shown to specifically target polyadenylated prematurely terminated RNAs for nuclear 319 degradation 15 , we suppose that CDK13 normally phosphorylates ZC3H14 to recruit the PAXT 320 complex to degrade aberrant RNAs made during failed transcriptional elongation. When CDK13 321 is mutated, failure to recruit the PAXT complex results in the accumulation of truncated 322 transcripts which are in turn translated into truncated proteins, contributing to aggressive 323 melanoma ( Figure S5B ). 324
The proteomic data suggest prematurely terminated transcripts that accumulate in CDK13 mel 325 expressing cells are translated into truncated proteins. We hypothesize that the acceleration of 326 melanoma progression we observe in tumors expressing CDK13 mel could be influenced by the 327 presence of these aberrant truncated proteins. Some of the proteins showing evidence of 328 truncation in our data are tumor suppressors that would be expected to lose functionality; others 329 may act in a dominant negative fashion to favor tumor progression [29] [30] [31] . 330
Recent reports suggest that prematurely terminated RNAs may be a newly recognized and 331 more generalized oncogenic mechanism. Widespread intronic polyadenylation events were 332 reported to disrupt tumor suppressor genes in leukemia by generating truncated mRNAs and 333 proteins, however the truncation mechanism was not defined 38 . Loss of function mutations in 334 CDK12 in metastatic castration-resistant prostate cancer and serous ovarian carcinomas were 335 reported to cause increased production of truncated RNAs in DNA repair genes 28,39 . The tumor 336 suppressor function of CDK13 appears to uniquely function to target truncated messages for 337 degradation via PAXT-dependent surveillance, representing an additional mechanism by which 338 the oncogenic activity of prematurely terminated RNAs is countered in normal cells. 339
Our data are consistent with the evolutionarily related CDK12 and CDK13 having related 340 but distinct functions (Table S1 ). Indeed, as known tumor suppressors their roles could be 341 complementary, with CDK12 preventing the early termination of transcripts and CDK13 342 promoting the degradation of any prematurely terminated message that escape CDK12-mediated 343 suppression. 344 Supplementary Table 4 . 360
Code Availability: Custom code is available upon request. 361
Patient mutation and survival analysis:
Overall survival, mutation, and expression data (z-362 score values) from the TCGA melanoma cohort 40 were downloaded on 4/7/17 using 363 cBioPortal 17 . A low-function CDK13 group was defined by either having a mutation in CDK13 364 or having low CDK13 expression, which was defined by z score equal to or less than -1.0. The 365 difference in survival between low-function CDK13 vs. remaining cases was tested using a log-366 rank test. The difference in survival between low-function CDK13 stage 0, 1, or 2 patients were 367 compared with remaining stage 1 or 2 patients. Mutation plot was downloaded on 4/7/17 and 368 percent mutations were calculated with all data sets available 4/7/17 using cBioPortal 17 , 369 excluding datasets from the Broad Institute, as it has duplicate samples with the DFCI/Broad set. 370 EGFP. In CRISPR experiments, control vectors expressed a gRNA to arhgap11a, a gene whose 377 knock out has the same tumor curve as no gRNA vector in our system. In experiments where 378 more than one vector was injected, DNA was prepared at 20ng/uL but divided equally between 379 included vectors. For most experiments, embryos were sorted for melanocyte rescue at 5dpf. For 380 cdk13 CRISPR, control CRISPR, CDK13 WT expression, and cdk13 CRISPR + CDK13 WT 381 expression embryos were sorted for melanocyte rescue, the 20 embryos with the most rescue 382 were collected, and they were imaged at 3dpf. In all experiments, 20 zebrafish were raised per 383 tank to control for density effects. Zebrafish were scored for the emergence of raised melanoma 384 lesions as published 21 . Melanoma-free survival curves and Log-rank tests were generated in 385
Prism. As melanocyte-specific cdk13 CRISPR/Cas9 zebrafish and melanocyte-specific CDK13 386
WT expressing zebrafish had few melanocytes as adults, tumor curves were not gathered. All 
Cloning (all except for mouse ES cells): 407
MiniCoopR (MCR) system 19,21 : Zebrafish MCR overexpression constructs using the mitfa 408 promoter, relevant coding sequence, 3' pA tail, and the MCR destination vector were assembled 409 with LR Clonase II Plus (Thermofisher, 12538120). Gene lists were subsetted and/or broken into equally sized groups using different 519 characteristics for different analyses. Unless otherwise noted, only genes greater than 2 kb from 520 their transcription start sites to their transcription end sites were used. 521
Fold-change metagenes used the subset of all genes regardless of length that were in the 20% 522 whose fold-changes in promoter CDK13 levels increased the most dramatically. The displayed 523 metagenes represent per-bin log2-fold ratios of the average values for Ser2-RNA Polymerase II 524 vs. the average values for total RNA Polymerase II where one pseudocount was added. 525
To study the effects of CDK13 mutation on coverage of genes expressed at different levels, 526 the gene list was broken into six equally sized groups by their mean expression across three 527 control samples for zebrafish samples. For human samples, the gene list was broken into five 528 equally sized groups and expression amounts were determined from ribo-depleted RNA-529 sequencing from the three CLOVER expressing A375 lines as described above in "Stable 530 Human Cell Lines". 531
To study the effects of CDK13 mutation on coverage of genes of different lengths, genes were 532 broken into six equally sized groups based on their gene length from transcription start site to 533 transcription end site. 534 bigWig files displaying read coverage were created using readGAlignments and coverage 535 from the GenomicAlignments 50 package and export.bw from the rtracklayer 51 package, where 536 putative PCR duplicate reads were removed. IGV (http://www.broadinstitute.org/igv) was used 537 to view bigWig files in figures. 538
For anti-CDK13 ChIP-sequencing from melanomas from mitfa:BRAFmut+/+; p53-/-; Na-/-539 zebrafish expressing either CDK13 R860Q + ccnT1 CRISPR or CDK13 R860Q + ctrl CRISPR, 540 coverage of zebrafish promoters was quantified by bamToGFF. Gene positions for the GRCz10 541 revision of the zebrafish genome were downloaded from Ensembl (version 90). Two different 542 windows were used: +/-2kb from the transcription start sites is displayed, and +/-250 bp from the 543 transcription start sites was used to order rows/regions. Regions for display were broken into 100 544 equally sized bins (-m 100 -r ), whereas ranking was done using a single window (-m 1 -r). In 545 each case, input signal was subtracted from the corresponding regions. Promoters were subsetted 546 for those that had background-subtracted RPM values in the 500 bp window > 1. They were 547 ordered by their log2 fold-change between sgCtrl and sgccnT1 background-subtracted coverage, 548 with one pseudocount added. 549
Zebrafish Melanoma RNA-seq and RNA-seq processing: 550
Zebrafish melanomas expressing EGFP, K734R, or R860Q in mitfa:BRAFmut+/+; p53-/-; Na-551 /-zebrafish were sacrificed on ice and the tumors were dissected, homogenized in RLT buffer, 552 subjected to QIAshredder columns (Qiagen, 79656), and then RNA was isolated with a column 553 based method with genomic DNA column removal (Qiagen, 74134). RNA was ribodepleted 554 (Illumina Ribozero Gold, MRZG12324). Ribodepletion was confirmed with Agilent 4200 555
Tapestation. Library prepped with random priming (NEBNext Ultra RNA Library Prep Kit for 556 Illumina, E7530), fragmentation time of 15min, 12 PCR cycles, and sequenced on an Illumina 557 HiSeq 2000 (100bp paired end reads). 558
Sequenced reads were mapped to a custom version of the danRer10 transcriptome where all 559 chromosomes were included plus human CDK13 using tophat 2.1.1 52 with parameters -library-560 type fr-unstranded -no-novel-juncs and -G set to a GTF of Ensembl zebrafish genes (v90). 561
Expression quantification was performed using htseq-count 53 using the same GTF as above and 562 parameters -r name -i gene_name -stranded=no -f bam -m intersection-strict. Gene-level 563 transcription read counts were then normalized to transcripts per million (TPM) (counts / bp in 564 exons of all isoforms / 1000 / total counts across all genes / 1000000). Differential expression 565 analysis was performed using DEseq2 54 with standard parameters comparing raw read counts in 566 all overexpression mutant samples against all overexpressed EGFP samples. 567
Mouse Embryonic Stem Cells: 568
Cell Culture, Cell Line Generation, Drug Conditions: 569
All cell lines were tested for mycoplasma contamination periodically, including immediately 570 after generation of CRISPR-modified clonal cell lines via the MycoAlert Mycoplasma Testing 571 Kit (Lonza). Results were always negative for mycoplasma contamination. V6.5 (C57Bl/6-129) 572 mESCs and derived cell lines were cultured on 0.2% gelatin-coated tissue culture plates in ES 573 media: Dulbecco's Modified Essential Media (Thermo Fisher) buffered with 10mM HEPES 574 (Thermo Fisher) and supplemented with 15% Fetal Bovine Serum (Hyclone), 1000U/mL 575 leukemia inhibitory factor (Millipore), 1x non-essential amino acids (Thermo Fisher), 2mM L-576 glutamine (Thermo Fisher), 0.11mM ß-mercaptoethanol (Sigma), 100 IU penicillin and 577 100ug/mL streptomycin (Corning). 578
Cdk13∆ clones were generated using CRISPR/Cas9 genome editing technology as follows 579 (see Figure S3B ). sgRNAs targeting intron 3 and intron 4 of the endogenous Cdk13 locus were 580 cloned into pX458 (a gift from Feng Zhang, Addgene plasmid #48138) 55 or pX330 (a gift from 581 Feng Zhang, Addgene# 42230) 56 respectively (see Supplementary Table. 3 for sequences). Two 582 independent pairs of sgRNAs (one sgRNA targeting intron 3 and one sgRNA targeting intron 4) 583 were co-transfected into wildtype V6.5 mouse embryonic stem cells with Lipofectamine®2000 584 (Thermo Fisher), and single-cell sorted for GFP+ fluorescence (transfected cells) 24 hours after 585 transfection. Clones were screened for homozygous deletion of exon 4 by PCR and confirmed by 586 sanger sequencing. Knockout of endogenous Cdk13 was confirmed by Western blot (Figures 587 S3C). One knockout clone from each sgRNA pair was used throughout the study to control for 588 off-target effects of the sgRNAs. 589
A Dox-inducible Cdk13 transgene was stably introduced into the two Cdk13∆ clones used 590 throughout this studying using a piggybac retrotransposon system. N-terminal Flag-HA-tandem epitope-tagged Cdk13 (NP_001074527.1 isoform) was cloned via overlap extension PCR using 592 two templates: (1) a synthetic gene block containing the codon-optimized N-terminus of Cdk13 593 (first 1577 base pairs) to reduce the high GC content in the region and (2) polyA-selected mouse 594 cDNA from V6.5 cells. This PCR product was cloned into pCR8/GW/TOPO (Thermo Fisher) 595 followed by transfer into the doxycycline-inducible piggybac expression vector, Dest (a gift from A.W. Cheng), using standard TOPO and Gateway cloning kits (Thermo Fisher). 597
The final Cdk13 transgene sequence is provided in Supplementary Table 5 Figure S3E ), and these two clones were used 607 throughout the study. 608
Western Blotting 609
Whole cell extract was harvested by washing the cells in cold phosphate-buffered saline 610 a01410). Secondary antibodies used: ECL Anti-Rat IgG (GE Healthcare NA935V), ECL Anti-623
Mouse IgG (GE Healthcare NA931V), and ECL Anti-Rabbit IgG (GE Healthcare NA934V). 624
RNA Sequencing: 625
Two independent Cdk13 clones with Dox-inducible Cdk13 were pre-treated with 1ug/mL 626 Doxycycline (Dox) daily for at least 5 days prior to the start of the time course to express 627 complementing levels of Cdk13 transgene in the Cdk13 background ( Figure S3D ). Dox was 628 withdrawn from these cells at time 0, which resulted in significant knockdown and undetectable 629 levels of Cdk13 after 48-or 72-hours respectively ( Figure S3E Table 4 ). For zebrafish melanomas, bams from above for CDK13 R860Q (n=5) and EGFP (n=4) 650 melanomas were used. For mouse ES cells, bams from above RNA-seq were used. 651
For each genome analyzed, The files were sorted using SAMtools 57 . All exons were assigned 652 to one of the following classes: 
